Unknown

Dataset Information

Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury.


ABSTRACT: Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving irinotecan. However, molecular mechanisms by which irinotecan-induced liver injury remain elusive. In this study, we found that irinotecan treatment caused significant elevation of ALT, inflammation, and fat accumulation in the liver, which are associated with hepatic macrophage activation. Depletion of macrophages by clodronate liposome improved irinotecan induced liver injury and inflammatory response in mice. In vitro data indicated that irinotecan induced intracellular ROS production in primary hepatocyte and upregulating of toll-like r

SUBMITTER: Liu B 

PROVIDER: S-EPMC9739808 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature